Viridian Therapeutics, Inc.\DE

By person

23 insiders · 71 transactions

1.1×

Stephen Mahoney holds only 1.1 times base salary in stock. $811.69K of shares against $700.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Stephen Mahoney last reported holding, valued at $24.50, the price Common Stock was last bought or sold at on the open market here, on 19 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Fairmount Funds Management LLC entity

Director

$90.00M (6)

—

+$90.00M

5,617,321

4.96%

$137.62M

+15,907%

Violin Jonathan

Chief Executive Officer

—

$4.27M (10)

−$4.27M

430,905

0.3803%

$10.56M

—

Katz Barrett

Chief Medical Officer

—

$3.17M (4) scheduled

−$3.17M

0.0000%

$0.00

—

Booth Bruce

Director

$3.00M (1)

—

+$3.00M

3,142,580

2.77%

$76.99M

+21.0%

Meisner Lara

Chief Legal Officer

—

$2.54M (14) scheduled

−$2.54M

29,971

0.0265%

$734.29K

−50.0%

Logos Global Master Fund LP entity

10% owner

$2.27M (3)

—

+$2.27M

550,000

0.4855%

$13.48M

+650.0%

Frazier Life Sciences Public Fund, L.P. entity

10% owner

$2.20M (1)

—

+$2.20M

1,505,200

1.33%

$36.88M

+15.3%

LEFKOFF KYLE

Director

—

$540.14K (10)

−$540.14K

463,473

0.4091%

$11.36M

−7.4%

Mahoney Stephen F.

President and CEO

$499.26K (1)

—

+$499.26K

33,130

0.0292%

$811.69K

+3,213%

Tousignant Jennifer

Chief Legal Officer

—

$418.99K (3) scheduled

−$418.99K

0.0000%

$0.00

−100.0%

Myers Scott Dunseth

Chief Executive Officer

$261.80K (2)

—

+$261.80K

259,500

0.2291%

$6.36M

—

Beetham Thomas W.

Chief Operating Officer

$117.05K (1)

—

+$117.05K

13,271

0.0117%

$325.14K

+563.6%

Levy Adam Scott

Chief Business Officer

$51.51K (2)

—

+$51.51K

13,040

0.0115%

$319.48K

+247.7%

Hughes Thomas E.

Director

$47.70K (1)

$96.00K (1)

−$48.30K

12,827

0.0113%

$314.26K

−8.7%

Riccitelli Samuel D

President & CEO

—

571,370

0.5043%

$14.00M

+20.4%

LEBOW BENNETT S

Director

—

429,441

0.3791%

$10.52M

+187.9%

Marshall William Stuart

See Remarks

—

273,146

0.2411%

$6.69M

+73.6%

FAVORITO TAMARA A

CFO, Secretary, Treasurer

—

106,447

0.0940%

$2.61M

+294.3%

Leverone Jason A.

Chief Financial Officer

—

48,829

0.0431%

$1.20M

+885.1%

Tripuraneni Radhika

Chief Medical Officer

—

40,000

0.0353%

$980.00K

—

Harmon Seth

Chief Financial Officer

—

7,790

0.0069%

$190.86K

+115.6%

Smith Robin L

Director

—

1,900

0.0017%

$46.55K

+171.4%

Gonyer David A

Director

—

1,899

0.0017%

$46.53K

+171.7%

Individual transactions

Insider

Date

Role

Action

Price

Amount

Fairmount Funds Management LLC

11 May 2026

Director

Buy indirect

1,176,470

$17.00

$20.00M

Fairmount Funds Management LLC

23 Oct 2025

Director

Buy indirect

454,545

$22.00

$10.00M

Mahoney Stephen F.

27 Sep 2024

President and CEO

Buy

21,400

$23.33

$499.26K

Beetham Thomas W.

27 Sep 2024

Chief Operating Officer

Buy

5,000

$23.41

$117.05K

Fairmount Funds Management LLC

13 Sep 2024

Director

Buy indirect

1,600,000

$18.75

$30.00M

Fairmount Funds Management LLC

22 Jan 2024

Director

Buy indirect

476,190

$21.00

$10.00M

Myers Scott Dunseth

12 Apr 2023

Chief Executive Officer

Buy

4,000

$25.37

$101.48K

Myers Scott Dunseth

13 Mar 2023

Chief Executive Officer

Buy

5,500

$29.15

$160.32K

Fairmount Funds Management LLC

17 Aug 2022

Director

Buy indirect

425,531

$23.50

$10.00M

Frazier Life Sciences Public Fund, L.P.

23 Sep 2021

10% owner

Buy

200,000

$11.00

$2.20M

Fairmount Funds Management LLC

21 Sep 2021

Director

Buy indirect

909,000

$11.00

$10.00M

Logos Global Master Fund LP

13 Nov 2020

10% owner

Buy

126,667

$14.84

$1.88M

Logos Global Master Fund LP

9 Nov 2020

10% owner

Buy

100,000

$1.16

$116.41K

Logos Global Master Fund LP

9 Nov 2020

10% owner

Buy

250,000

$1.10

$274.48K

Hughes Thomas E.

11 Oct 2018

Director

Buy

10,000

$4.77

$47.70K

Booth Bruce

13 Feb 2018

Director

Buy indirect

545,454

$5.50

$3.00M

Levy Adam Scott

13 Feb 2018

Chief Business Officer

Buy

9,090

$5.50

$50.00K

Levy Adam Scott

22 Jun 2017

Chief Business Officer

Buy

200

$7.55

$1.51K

Show all 71 transactions →

Viridian Therapeutics, Inc.\DE

By person

Individual transactions

What was left out